title: Embryotrophic factor-3 from human oviductal cells affects the messenger RNA expression of mouse blastocyst.
abstract: Our previous results showed that embryotrophic factor-3 (ETF-3) from human oviductal cells increased the size and hatching rate of mouse blastocysts in vitro. The present study investigated the production of ETF-3 by an immortalized human oviductal cell line (OE-E6/E7) and the effects of ETF-3 on the mRNA expression of mouse embryos. The ETF-3 was purified from primary oviductal cell conditioned media using sequential liquid chromatographic systems, and antiserum against ETF-3 was raised. The ETF-3-supplemented Chatot-Ziomek-Bavister medium was used to culture Day 1 MF1 x BALB/c mouse embryos for 4 days. The ETF-3 treatment significantly enhanced the mouse embryo blastulation and hatching rate. The antiserum, at concentrations of 0.03-3%, abolished the embryotrophic effect of ETF-3. Positive ETF-3 immunoreactivity was detected in the primary oviductal cells, OE-E6/E7, and blastocysts derived from ETF-3 treatment. Vero cells (African Green Monkey kidney cell line), fibroblasts, and embryos cultured in control medium did not possess ETF-3 immunoreactivity. The mRNA expression patterns of the treated embryos were studied at the blastocyst stage by mRNA differential display reverse transcription-polymerase chain reaction (DDRT-PCR). The DDRT-PCR showed that some of the mRNAs were differentially expressed after ETF-3 treatment. Twelve of the differentially expressed mRNAs that had high homology with cDNA sequences in the GenBank were selected for further characterization. The differential expression of seven of these mRNAs (ezrin, heat shock 70-kDa protein, cytochrome c oxidase subunit VIIa-L precursor, proteinase-activated receptor 2, eukaryotic translation initiation factor 2beta, cullin 1, and proliferating cell nuclear antigen) was confirmed by semiquantitative RT-PCR. In conclusion, immortalized oviductal cells produce ETF-3, which influences mRNA expression of mouse blastocyst.
authors.affiliation: Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
authors.forename: Y L
authors.initials: YL
authors.lastname: Lee
authors.forename: K F
authors.initials: KF
authors.lastname: Lee
authors.forename: J S
authors.initials: JS
authors.lastname: Xu
authors.forename: K L
authors.initials: KL
authors.lastname: Kwok
authors.forename: J M
authors.initials: JM
authors.lastname: Luk
authors.forename: W M
authors.initials: WM
authors.lastname: Lee
authors.forename: W S B
authors.initials: WS
authors.lastname: Yeung
mesh_terms: D000818:Animals; D001755:Blastocyst / Q000187:drug effects* / Q000378:metabolism*; D002461:Cell Line, Transformed; D002522:Chlorocebus aethiops; D046508:Culture Techniques; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005455:Fluorescent Antibody Technique; D006133:Growth Substances / Q000276:immunology / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010057:Oviducts / Q000737:chemistry*; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014709:Vero Cells
chemical_list: D006133:Growth Substances; D007106:Immune Sera; D012333:RNA, Messenger